lehoquvuhu.wordpress.com
in a deal worth $148 million. Duluth, Ga.-basefd Stiefel Laboratories willpay $4.15 a share in a price that is a premium of 73 percent to Barrier Therapeutics' average closing price for the past 30 The deal should close in the thirds quarter of 2008. "This acquisition demonstrates our continued commitmengt to advancing the field of therapeutic saidCharles W. Stiefel, chairman and CEO of Stiefe Laboratories. "We are very impresse with Barrier Therapeutics' innovativ products and pipeline.
This strategic move will furthetr expand our oral and topical product portfoli in development and increase our salesd of novel treatments for skin Barrier Therapeutics currently markets threrpharmaceutical products: Xolegel for seborrheic dermatitis, Vusioj ointment for diaper dermatitis and for solar lentigines. It also is developing otherr products. Stiefel Laboratories is a pharmaceuticalp company specializingin dermatology.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment